<DOC>
	<DOCNO>NCT01728025</DOCNO>
	<brief_summary>The purpose study determine whether ranolazine reduce risk arrhythmic event patient long QT syndrome type 3 .</brief_summary>
	<brief_title>Long Term Prophylactic Therapy Congenital Long QT Syndrome Type III ( LQT3 ) With Ranolazine</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Long QT patient genetic confirmation carrierstatus D1790G mutation SCN5A gene Corrected QT interval &gt; 460 msec Need therapy medication potent moderately potent CYP3A inhibitor ( ketoconazole , diltiazem , verapamil , macrolide antibiotic HIV protease inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Long QT syndrome</keyword>
	<keyword>Ranolazine</keyword>
</DOC>